SCHEMBL21187357

SCHEMBL21187357

Cc1nccc(N[C@H]2CC[C@@H](Oc3cc(N4CCOCC4)cc4ncncc34)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 5/20 0.38
PIK3C3 Q8NEB9 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
PDE10A Q9Y233 2/20 0.36
IKBKE Q14164 3/20 0.36
TBK1 Q9UHD2 3/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
PRKDC P78527 3/20 0.36
TTK P33981 1/20 0.36
CDK4 P11802 1/20 0.35
CCNA2 P20248 1/20 0.35
CCND1 P24385 1/20 0.35
CDK2 P24941 1/20 0.35
CCND3 P30281 1/20 0.35
CDK6 Q00534 1/20 0.35
GPR6 P46095 1/20 0.35
SYK P43405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22635848 1.00 IRAK4 (0.38) IRAK4PIK3C3CCNCCDK8PDE10A
SCHEMBL21187333 0.91 PIK3C3 (0.39) PIK3C3PDE10AIKBKETBK1JAK2
SCHEMBL30823279 0.91 PIK3C3 (0.39) PIK3C3PDE10AIKBKETBK1JAK2
SCHEMBL28471538 0.91 PIK3C3 (0.39) PIK3C3PDE10AIKBKETBK1JAK2
SCHEMBL21187290 0.90 CCNC (0.37) IRAK4CCNCCDK8PDE10AIKBKE
SCHEMBL21178253 0.90 CCNC (0.37) IRAK4CCNCCDK8PDE10AIKBKE
SCHEMBL21179460 0.88 TBK1 (0.39) IRAK4CCNCCDK8IKBKETBK1
SCHEMBL21187294 0.88 TBK1 (0.39) IRAK4CCNCCDK8IKBKETBK1
SCHEMBL21187285 0.87 PIK3C3 (0.38) IRAK4PIK3C3PDE10AIKBKETBK1
SCHEMBL21177801 0.85 PRKDC (0.39) IRAK4CCNCCDK8TBK1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200353101-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2020-11-12 US disclosed
WO-2019143678-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200353101-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1175/4885PIK3C3 1839/4885CCNC 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.